tiprankstipranks
Procept Biorobotics Corp. (PRCT)
NASDAQ:PRCT
US Market
PRCT
PROCEPT BioRobotics
RESEARCH TOOLSreports
Want to see PRCT full AI Analyst Report?

PROCEPT BioRobotics (PRCT) Stock Forecast & Price Target

665 Followers
See the Price Targets and Ratings of:

PRCT Analyst Ratings

Hold
11Ratings
Hold
3 Buy
7 Hold
1 Sell
Based on 11 analysts giving stock ratings to
PROCEPT
BioRobotics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PRCT Stock 12 Month Forecast

Average Price Target

$23.13
▲(38.56% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for PROCEPT BioRobotics in the last 3 months. The average price target is $23.13 with a high forecast of $29.00 and a low forecast of $19.00. The average price target represents a 38.56% change from the last price of $16.69.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"$17","50":"$50","25.25":"$25.3","33.5":"$33.5","41.75":"$41.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$29.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$23.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$19.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,25.25,33.5,41.75,50],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.62,19.41846153846154,20.216923076923077,21.015384615384615,21.813846153846153,22.61230769230769,23.410769230769233,24.20923076923077,25.00769230769231,25.806153846153848,26.604615384615386,27.403076923076924,28.201538461538462,{"y":29,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.62,18.966538461538462,19.313076923076924,19.659615384615385,20.006153846153847,20.35269230769231,20.69923076923077,21.04576923076923,21.392307692307693,21.738846153846154,22.085384615384616,22.431923076923077,22.77846153846154,{"y":23.125,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.62,18.64923076923077,18.67846153846154,18.70769230769231,18.736923076923077,18.76615384615385,18.795384615384616,18.824615384615385,18.853846153846153,18.883076923076924,18.912307692307692,18.94153846153846,18.970769230769232,{"y":19,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":49.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.57,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.73,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.03,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.41,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.46,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.14,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.9,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.36,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.63,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.86,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.47,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.62,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$29.00Average Price Target$23.13Lowest Price Target$19.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on PRCT
Brandon Vazquez
William Blair
William Blair
―
Hold
―
Downgraded
08/08/26
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (NASDAQ: PRCT) and Achieve Life Sciences (NASDAQ: ACHV)
Truist Financial Analyst forecast on PRCT
Richard Newitter
Truist Financial
Truist Financial
$25→$21
Hold
25.82%
Upside
Reiterated
08/05/26
Truist Financial Keeps Their Hold Rating on PROCEPT BioRobotics (PRCT)
Evercore ISI Analyst forecast on PRCT
Vijay Kumar
Evercore ISI
Evercore ISI
$30→$23
Buy
37.81%
Upside
Reiterated
08/05/26
Procept BioRobotics price target lowered to $23 from $30 at Evercore ISIProcept BioRobotics price target lowered to $23 from $30 at Evercore ISI
TD Cowen Analyst forecast on PRCT
Josh Jennings
TD Cowen
TD Cowen
$34→$28
Buy
67.77%
Upside
Assigned
08/05/26
Analyst Maintains Buy on PROCEPT BioRobotics, Citing Strong Growth Drivers Despite Price Target Cut to $28
BTIG Analyst forecast on PRCT
Ryan Zimmerman
BTIG
BTIG
―
Hold
―
Reiterated
08/05/26
PROCEPT BioRobotics: Strong System Sales Offset by Weakening Procedure Trends Keep Rating at Hold
Robert W. Baird Analyst forecast on PRCT
David Rescott
Robert W. Baird
Robert W. Baird
$24→$20
Hold
19.83%
Upside
Reiterated
08/05/26
Procept BioRobotics price target lowered to $20 from $24 at BairdProcept BioRobotics price target lowered to $20 from $24 at Baird
Bank of America Securities Analyst forecast on PRCT
Stephanie Piazzola
Bank of America Securities
Bank of America Securities
―
Sell
―
Reiterated
08/05/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Stevanato Group (NYSE: STVN), Ultragenyx Pharmaceutical (NASDAQ: RARE) and PROCEPT BioRobotics (NASDAQ: PRCT)
Wells Fargo Analyst forecast on PRCT
Nathan Treybeck
Wells Fargo
Wells Fargo
$34→$19
Hold
13.84%
Upside
Downgraded
08/05/26
Procept BioRobotics downgraded to Equal Weight from Overweight at Wells FargoProcept BioRobotics downgraded to Equal Weight from Overweight at Wells Fargo
UBS Analyst forecast on PRCT
Patrick Wood
UBS
UBS
$20
Hold
19.83%
Upside
Reiterated
08/05/26
PROCEPT BioRobotics: Neutral/Hold Rating Reflects Weaker Procedure Growth Outlook and Delayed Profitability Despite Solid Revenue and International Expansion
Piper Sandler Analyst forecast on PRCT
Matthew O'Brien
Piper Sandler
Piper Sandler
$35→$25
Buy
49.79%
Upside
Reiterated
08/05/26
Piper Sandler Sticks to Its Buy Rating for PROCEPT BioRobotics (PRCT)
Leerink Partners Analyst forecast on PRCT
Mike Kratky
Leerink Partners
Leerink Partners
$31→$29
Hold
73.76%
Upside
Downgraded
06/12/26
Procept BioRobotics downgraded to Market Perform from Outperform at LeerinkProcept BioRobotics downgraded to Market Perform from Outperform at Leerink
Oppenheimer Analyst forecast on PRCT
Suraj Kalia
Oppenheimer
Oppenheimer
$60
Hold
259.50%
Upside
Downgraded
02/26/26
Procept BioRobotics downgraded to Perform from Outperform at OppenheimerProcept BioRobotics downgraded to Perform from Outperform at Oppenheimer
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on PRCT
Brandon Vazquez
William Blair
William Blair
―
Hold
―
Downgraded
08/08/26
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (NASDAQ: PRCT) and Achieve Life Sciences (NASDAQ: ACHV)
Truist Financial Analyst forecast on PRCT
Richard Newitter
Truist Financial
Truist Financial
$25→$21
Hold
25.82%
Upside
Reiterated
08/05/26
Truist Financial Keeps Their Hold Rating on PROCEPT BioRobotics (PRCT)
Evercore ISI Analyst forecast on PRCT
Vijay Kumar
Evercore ISI
Evercore ISI
$30→$23
Buy
37.81%
Upside
Reiterated
08/05/26
Procept BioRobotics price target lowered to $23 from $30 at Evercore ISIProcept BioRobotics price target lowered to $23 from $30 at Evercore ISI
TD Cowen Analyst forecast on PRCT
Josh Jennings
TD Cowen
TD Cowen
$34→$28
Buy
67.77%
Upside
Assigned
08/05/26
Analyst Maintains Buy on PROCEPT BioRobotics, Citing Strong Growth Drivers Despite Price Target Cut to $28
BTIG Analyst forecast on PRCT
Ryan Zimmerman
BTIG
BTIG
―
Hold
―
Reiterated
08/05/26
PROCEPT BioRobotics: Strong System Sales Offset by Weakening Procedure Trends Keep Rating at Hold
Robert W. Baird Analyst forecast on PRCT
David Rescott
Robert W. Baird
Robert W. Baird
$24→$20
Hold
19.83%
Upside
Reiterated
08/05/26
Procept BioRobotics price target lowered to $20 from $24 at BairdProcept BioRobotics price target lowered to $20 from $24 at Baird
Bank of America Securities Analyst forecast on PRCT
Stephanie Piazzola
Bank of America Securities
Bank of America Securities
―
Sell
―
Reiterated
08/05/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Stevanato Group (NYSE: STVN), Ultragenyx Pharmaceutical (NASDAQ: RARE) and PROCEPT BioRobotics (NASDAQ: PRCT)
Wells Fargo Analyst forecast on PRCT
Nathan Treybeck
Wells Fargo
Wells Fargo
$34→$19
Hold
13.84%
Upside
Downgraded
08/05/26
Procept BioRobotics downgraded to Equal Weight from Overweight at Wells FargoProcept BioRobotics downgraded to Equal Weight from Overweight at Wells Fargo
UBS Analyst forecast on PRCT
Patrick Wood
UBS
UBS
$20
Hold
19.83%
Upside
Reiterated
08/05/26
PROCEPT BioRobotics: Neutral/Hold Rating Reflects Weaker Procedure Growth Outlook and Delayed Profitability Despite Solid Revenue and International Expansion
Piper Sandler Analyst forecast on PRCT
Matthew O'Brien
Piper Sandler
Piper Sandler
$35→$25
Buy
49.79%
Upside
Reiterated
08/05/26
Piper Sandler Sticks to Its Buy Rating for PROCEPT BioRobotics (PRCT)
Leerink Partners Analyst forecast on PRCT
Mike Kratky
Leerink Partners
Leerink Partners
$31→$29
Hold
73.76%
Upside
Downgraded
06/12/26
Procept BioRobotics downgraded to Market Perform from Outperform at LeerinkProcept BioRobotics downgraded to Market Perform from Outperform at Leerink
Oppenheimer Analyst forecast on PRCT
Suraj Kalia
Oppenheimer
Oppenheimer
$60
Hold
259.50%
Upside
Downgraded
02/26/26
Procept BioRobotics downgraded to Perform from Outperform at OppenheimerProcept BioRobotics downgraded to Perform from Outperform at Oppenheimer
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering PROCEPT BioRobotics

3 Months
Matthew O'BrienPiper Sandler
Success Rate
10/17 ratings generated profit
59%
Average Return
+6.75%
Copying Matthew O'Brien's trades and holding each position for 3 Months would result in 58.82% of your transactions generating a profit, with an average return of +6.75% per trade.
1 Year
Matthew O'BrienPiper Sandler
Success Rate
6/17 ratings generated profit
35%
Average Return
+2.14%
Copying Matthew O'Brien's trades and holding each position for 1 Year would result in 35.29% of your transactions generating a profit, with an average return of +2.14% per trade.
2 Years
Matthew O'BrienPiper Sandler
Success Rate
2/17 ratings generated profit
12%
Average Return
-36.51%
Copying Matthew O'Brien's trades and holding each position for 2 Years would result in 11.76% of your transactions generating a profit, with an average return of -36.51% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PRCT Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
2
2
1
1
1
Buy
16
13
11
7
7
Hold
7
4
5
6
13
Sell
1
1
1
1
1
Strong Sell
0
0
0
0
0
total
26
20
18
15
22
In the current month, PRCT has received 8 Buy Ratings, 13 Hold Ratings, and 1 Sell Ratings. PRCT average Analyst price target in the past 3 months is 23.13.
Each month's total comprises the sum of three months' worth of ratings.

PRCT Financial Forecast

PRCT Earnings Forecast

Next quarter’s earnings estimate for PRCT is -$0.39 with a range of -$0.43 to -$0.34. The previous quarter’s EPS was -$0.47. PRCT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.64% of the time in the same period. In the last calendar year PRCT has Performed in-line its overall industry.
Next quarter’s earnings estimate for PRCT is -$0.39 with a range of -$0.43 to -$0.34. The previous quarter’s EPS was -$0.47. PRCT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.64% of the time in the same period. In the last calendar year PRCT has Performed in-line its overall industry.

PRCT Sales Forecast

Next quarter’s sales forecast for PRCT is $101.03M with a range of $96.20M to $103.60M. The previous quarter’s sales results were $94.50M. PRCT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year PRCT has Performed in-line its overall industry.
Next quarter’s sales forecast for PRCT is $101.03M with a range of $96.20M to $103.60M. The previous quarter’s sales results were $94.50M. PRCT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year PRCT has Performed in-line its overall industry.

PRCT Stock Forecast FAQ

What is PRCT’s average 12-month price target, according to analysts?
Based on analyst ratings, Procept Biorobotics Corp.’s 12-month average price target is 23.13.
    What is PRCT’s upside potential, based on the analysts’ average price target?
    Procept Biorobotics Corp. has 38.56% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PRCT a Buy, Sell or Hold?
          Procept Biorobotics Corp. has a consensus rating of Hold which is based on 3 buy ratings, 7 hold ratings and 1 sell ratings.
            What is Procept Biorobotics Corp.’s price target?
            The average price target for Procept Biorobotics Corp. is 23.13. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $29.00 ,the lowest forecast is $19.00. The average price target represents 38.56% Increase from the current price of $16.69.
              What do analysts say about Procept Biorobotics Corp.?
              Procept Biorobotics Corp.’s analyst rating consensus is a Hold. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of PRCT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.